Search PubMed⌕ Search

Biomedical subjects

M Sas

Publications and source records attributed to M Sas.

At least 55 records · Page 3Linked to original sources
PubMed1984

Gonadotrophin treatment of pathospermic patients.

The effectiveness of gonadotrophin treatment was studied in pathospermic patients. In the treatment of 10, 478 and 184 infertile men, Anthrogon, Choriogonin and Pergonal + HCG, respectively, were applied. Improvement of the spermiogram is anticipated especially when the pre-treatment plasma FSH level is low or normal. No success could be expected in hypergonadotrophic cases. Gonadotrophin treatment is not effective when infertility is due to genetic, mechanical, vascular or infectious diseases.

Chorionic Gonadotropin↗
PubMed1984

Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives.

WHO conducted a three-centre study in Hungary and Thailand to evaluate the effects of hormonal contraception on lactation and infant growth. Women choosing oral contraceptives were randomly assigned to a combined oral contraceptive containing 30 micrograms ethinyl estradiol and 150 micrograms levonorgestrel (N = 86) or a progestin-only preparation containing 75 micrograms dl-norgestrel (N = 85). Identical packaging and treatment schedules allowed double-blind observation. One-hundred-and-eleven women using no contraception or non-hormonal methods acted as controls. In the two Thai centres 59 women using depot-medroxyprogesterone acetate formed an additional comparison group. All subjects were healthy women with normal deliveries, whose infants had normal birth weights and satisfactory growth in the neonatal period. Breast milk volume was determined by pump expression using standardized procedures. Information was obtained on nursing frequency and supplementation, infant growth and morbidity. Pretreatment observations at 6 weeks post-partum were used as a baseline, and subjects were followed-up at 9, 12, 16, 20 and 24 weeks post-partum. Women using combined oral contraceptives had a decline in milk volume within 6 weeks of initiating treatment, whereas no significant decrease was observed in the other treatment groups. After 18 weeks of treatment, combined oral contraceptive users experienced a 41.9% decline in milk volume, compared to 12.0% with progestin-only minipills and 6.1% in the non-hormonal controls. The prevalence of complementary feeding and withdrawals due to inadequate milk supply were comparable in the four treatment groups. However, data were not available on the daily amounts of complementary feeds. There were no significant differences in growth of infants between treatment groups. Thus, women may have compensated for declines in milk volume by more supplementary feeding or by more prolonged and intense suckling episodes. We conclude that 30 micrograms estrogen-containing combined oral contraceptives impair milk secretion, but in the selected healthy group of mothers and children studied with the prevailing level of supplementary feeding, this did not adversely affect infant growth.

Adult↗
PubMed1984

Termination of very early pregnancy by RU 486--an antiprogestational compound.

RU 486, a new antiprogestational compound, was given to 37 women seeking termination of pregnancy and with amenorrhea of 42 days or less. One patient was found at the second follow-up visit to have an extrauterine pregnancy. The patients received either 25 mg, 50 mg or 100 mg RU 486 twice daily for four days. All patients attended three follow-up visits, one, two and five to six weeks after the start of therapy. The start, duration and amount of bleeding as well as plasma progesterone, beta-hCG and cortisol concentrations were determined for each treatment day and at the follow-up visits. All patients but three started to bleed during treatment. Frequency of complete abortion was 61% (22 out of 36 patients). In only three patients was the pregnancy unaffected by treatment. The clinical efficacy of the treatment was not dose-dependent. Most of the patients experienced only minor side effects in terms of mild uterine pain, nausea and vomiting. However, two patients suffered from heavy bleeding requiring blood transfusion and curettage. In the patients with complete abortion, beta-hCG values decreased significantly but not until the first follow-up visit. The plasma progesterone also decreased. The decrease appeared earlier with the higher daily dose of RU 486. Cortisol concentrations increased during treatment with all 3 dosage regimens but the levels remained within the normal range. It is concluded that treatment with RU 486 may provide a novel therapy for "menstrual regulation" but the efficacy of the treatment needs to be improved to compete with alternatives such as vacuum aspiration.

Abortifacient Agents↗
PubMed1984

Biological, microscopic and scanning electron microscopic investigations of the effects of postinor /d-norgestrel/ in rabbits.

The contraceptive effect of d-norgestrel given immediately after copulation in various quantities was investigated in rabbits. It was established that the effect is dose-dependent. A correlation was found between the amount of dose administered and the changes taking place on the surface of endometrium. It can be suggested that d-norgestrel alters the surface of the endometrium to such an extent that nidation is unable to take place; therefore, it can be used for postcoital contraception at any time.

Animals↗
PubMed1984

Relaxin in human decidua and term placenta.

Using both a homologous porcine RIA and 3 bioassays, we investigated the relaxin content of human decidua from first trimester and term gestations and of placentas at term. Aqueous extracts of these tissues yielded only between 211 and 1090 pg immunoreactive relaxin/g fresh tissue. Neither acetonehexane extraction, octadecylsilica cartridge elution nor molecular sieve chromatography increased these relaxin levels. Compared with term decidua, first trimester decidua contained significantly higher levels of immunoreactive relaxin. In vitro studies did not evidence significant relaxin production by either decidual or placental tissues, even in the presence of decidual prolactin production. These results are in direct contrast to earlier reports of high concentrations of relaxin in decidua and placenta.

Animals↗
PubMed1984

[Prolactin-producing hypophyseal adenomas].

It is a report about the diagnostic and the therapy of 10 women with a hyperprolactinemia caused by microadenomas of the hypophysis. The diagnose was made by reason of clinical symptomatology and hormonal and neuroradiological investigations. In six cases the tumor was removed by transsphenoidal route. One women does not give her consent to the microsurgical operation. In three patients the operation seemed not to be indicated absolutely. We gave them a longlasting therapy with bromocriptine. After operation galactorrhea decreased and we found ovulatory cycles in any case. It was concluded, that the results may be better, if the patients are dealt with bromocriptine for a long time, so abolishing the still existing complaints.

Adenoma↗
PubMed1984

Response of the cervical factor to combined treatment with clomiphene and ethinyl-oestradiol.

Combined clomiphene + ethinyl-oestradiol therapy was applied to 103 women with functional infertility. Ovulatory responses were obtained with clomiphene in a number of cases, but no pregnancy ensued. Ethinyl-oestradiol was then administered in low doses together with clomiphene over 3 cycles until the day before the expected date of ovulation. This resulted in a further increase in the number of ovulatory cycles, and one-third of the women had become pregnant. Comparing the two types of treatment on the basis of quality, quantity and sperm-penetration of the cervical mucus, low doses of oestradiol were found to affect these parameters favourably. If the treatment is unsuccessful, i.e. if the parameters of mucus or of the conditions of penetration fail to respond, further investigations are required to find out whether a permanent damage to the cervical epithelium or some penetration disorder of immunological origin is responsible for the infertility.

Adult↗
PubMed1983

Characterization of luteal function by measuring the cumulative concentration of serum progesterone and urine pregnanediol-3 alpha-monoglucuronide.

The corpus luteum function of healthy, fertile women was established by measuring the serum progesterone and the early-morning urine pregnanediol-3 alpha-monoglucuronide levels during the ovulation cycles. Integration of the results led to a parameter, the luteal index (Ll), which represents the overall hormone production that characterizes the luteal function quantitatively much better than the criteria used so far. The average of the integrated hormone concentrations (Ll) for progesterone and pregnanediol were 451.4 nmol/l X time and 151.3 mumol/l X time respectively. Statistical analyses show that values of luteal index below 348.9 nmol/l X time progesterone and 134.5 mumol/l X time pregnanediol can be regarded, with very high probability, as symptomatic of luteal dysfunction. The course of the production of both progesterone and pregnanediol is characterized. The importance of these parameters in functional infertility is discussed.

Adult↗